PanTher Therapeutics

About Us

Mission

Our mission is to redefine cancer treatment with therapeutics designed to act precisely at the tumor site for enhanced clinical outcomes and minimal side effects.

Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. By packaging the therapeutics in customized form factors, we can deliver the full dose to the tumoral area and release it locally at high concentrations over an extended period of time. In short, we put all the drug where it is needed.

Targeted, sustained treatments directly at the tumor site

PanTher engineers customized therapeutic solutions to address the specific challenges dictated by tumor type, location, and therapeutic regimen. Several flexible form factors can be designed to enhance maximal locoregional accumulation of a plethora of active agents. The lead candidate, PTM-101, is a biodegradable film for the treatment of pancreatic cancer currently in a Phase 1 trial.

Our platform is widely applicable to many cancer and non-cancer treatments and our name reflects this philosophy.

[ Pan ] from Greek,
meaning “all”
+
[ Ther ] in reference to
therapy

Our History

PanTher was founded in 2016 to develop technology invented in the labs at Massachusetts Institute of Technology (MIT) and Harvard Medical School.

2016

  • Proof Of Concept data
  • Company spun out with Seed Round
  • Scale up manufacturing to clinically relevant prototype
  • IND-enabling study demonstrating efficacy, safety, and deployment to the site in clinical settings

2021

  • Closed successful Series A
  • Initiation of first clinical trial

Leadership Team

PanTher’s skilled management team offers years of experience in oncology, biomedical implantable therapeutics, regulatory affairs, and entrepreneurship. Our diverse set of expertise is the foundation of our success.

Laura Indolfi, PhD

Chief Executive Officer and Co‑Founder

David Ting, MD

Scientific Co-Founder

Elazer Edelman, MD, PhD

Scientific Co-Founder

Meg Lashof-Sullivan, PhD

Director of R&D

Sara Fanning

Director of Business Operations

Chris Johnson, PhD

Scientist

Chelsea Reinhold

Clinical Operation Support

Dan Wildman

Strategic Advisor

David Mackey

Corporate Finance Advisor and Board Observer

Board of Directors

Laura Indolfi, PhD

Chief Executive Officer and Co‑Founder

David Ting, MD

Scientific Co-Founder

Darshana Zaveri

Managing Partner,
Catalyst Health Ventures

Manish Bhandari, MD, E-MBA

Managing Partner,
Angel Physicians Fund

Maria Palasis, PhD

Chief Executive Officer,
Lyra Therapeutics

Clinical Advisory Board

Thomas E. Clancy, MD, FACS

Dana-Farber Cancer Institute

Jason Fleming, MD, FACS

Moffitt Cancer Center

Timothy B. Gardner, MD

Dartmouth-Hitchcock Medical Center

Theodore Hong, MD

Massachusetts General Hospital​